Evidence map›Paper›PMID 39910635›Full record

ReviewOrphanet journal of rare diseases2025

The mutational landscape of ARMC5 in Primary Bilateral Macronodular Adrenal Hyperplasia: an update.

Lucas Bouys, Anna Vaczlavik, Isadora P Cavalcante, Florian Violon, Anne Jouinot, Annabel Berthon, Patricia Vaduva, Stéphanie Espiard, Karine Perlemoine, Peter Kamenicky and 13 more

Abstract readReview
In one paragraph

Review in Orphanet journal of rare diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. First case report of theAME case reports · 2026
    Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Lucas Bouys *Université Paris-Cité, Institut Cochin, Inserm U1016, CNRS UMR 8104, Paris, France.
Anna Vaczlavik *Université Paris-Cité, Institut Cochin, Inserm U1016, CNRS UMR 8104, Paris, France.
Isadora P CavalcanteUniversité Paris-Cité, Institut Cochin, Inserm U1016, CNRS UMR 8104, Paris, France.
Florian ViolonUniversité Paris-Cité, Institut Cochin, Inserm U1016, CNRS UMR 8104, Paris, France.
Anne JouinotUniversité Paris-Cité, Institut Cochin, Inserm U1016, CNRS UMR 8104, Paris, France.
Annabel BerthonUniversité Paris-Cité, Institut Cochin, Inserm U1016, CNRS UMR 8104, Paris, France.
Patricia VaduvaUniversité Paris-Cité, Institut Cochin, Inserm U1016, CNRS UMR 8104, Paris, France.
Stéphanie EspiardDepartment of Endocrinology, Diabetology, Metabolism and Nutrition, CHU Lille, Inserm U1190, Lille, France.
Karine PerlemoineUniversité Paris-Cité, Institut Cochin, Inserm U1016, CNRS UMR 8104, Paris, France.
Peter KamenickyUniversité Paris-Saclay, Inserm, Physiologie et Physiopathologie Endocriniennes, Department of Endocrinology and Reproduction, Reference Center for Rare Pituitary Diseases, Hôpital Bicêtre, Assistance Publique Hôpitaux de Paris, Le Kremlin-Bicêtre, France.
Marie-Christine VantyghemDepartment of Endocrinology, Diabetology, Metabolism and Nutrition, CHU Lille, Inserm U1190, Lille, France.
Antoine TabarinDepartment of Endocrinology, Diabetology and Nutrition, Hôpital Haut-Lévêque, CHU Bordeaux, Bordeaux, France.
Gérald RaverotDepartment of Endocrinology, Groupement Hospitalier Est, Hospices Civils de Lyon, Bron, France.
Cristina L RonchiInstitute of Metabolism and System Research, University of Birmingham, Birmingham, UK.
Ulrich DischingerDivision of Endocrinology and Diabetes, Department of Internal Medicine I, University Hospital of Würzburg, Würzburg, Germany.
Martin ReinckeMedizinische Klinik und Poliklinik IV, Klinikum der Universität München, Munich, Germany.
Maria C FragosoDepartment of Endocrinology, Adrenal Unit, University of Sao Paulo, Sao Paulo, Brazil.
Constantine A StratakisSection on Endocrinology and Genetics, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health (NIH), Bethesda, MD, USA.
Albain ChansavangUniversité Paris-Cité, Institut Cochin, Inserm U1016, CNRS UMR 8104, Paris, France.
Eric PasmantUniversité Paris-Cité, Institut Cochin, Inserm U1016, CNRS UMR 8104, Paris, France.
Bruno RagazzonUniversité Paris-Cité, Institut Cochin, Inserm U1016, CNRS UMR 8104, Paris, France.
Jérôme BertheratUniversité Paris-Cité, Institut Cochin, Inserm U1016, CNRS UMR 8104, Paris, France. jerome.bertherat@aphp.fr.ORCID http://orcid.org/0000-0003-2551-3008
COMETE and ENSAT Networks

Funding

Agence Nationale pour la Recherche ANR-18-CE14-0008-01Deutsche Forschuungsgemeinschaft 314061271-TRR 205Else Kröner-Fresenius-Stiftung 2012_A103Else Kröner-Fresenius-Stiftung 2015_A228European Reference Network on Rare Endocrine Conditions 739572Fondation pour la Recherche Médicale EQU201903007854
6 · The paper itself

Abstract

backgroundPrimary Bilateral Macronodular Adrenal Hyperplasia (PBMAH) is a rare cause of Cushing's syndrome due to bilateral adrenocortical macronodules. Germline inactivating variants of the tumor suppressor gene ARMC5 are responsible for 20-25% of apparently sporadic PBMAH cases and 80% of familial presentations. ARMC5 screening is now routinely performed for PBMAH patients and families. Based on literature review and own observation, this study aims to give an overview of both published and unpublished ARMC5 genetic alterations and to compile the available evidence to discriminate pathogenic from benign variants.

results146 different germline variants (110 previously published and 36 novel) are identified, including 46% missense substitutions, 45% truncating variants, 3% affecting splice sites, 4% in-frame variants and 2% large deletions. In addition to the germline events, somatic 16p loss-of-heterozygosity and 104 different somatic events are described. The pathogenicity of ARMC5 variants is established on the basis of their frequency in the general population, in silico predictions, familial segregation and tumor DNA sequencing.

conclusionsThis is the first extensive review of ARMC5 pathogenic variants. It shows that they are spread on the whole coding sequence. This is a valuable resource for genetic investigations of PBMAH and will help the interpretation of new missense substitutions that are continuously identified.

Indexed as

MutationTumor Suppressor ProteinsArmadillo Domain ProteinsCushing SyndromeGerm-Line MutationHumansArmadillo Domain ProteinsARMC5 protein, humanTumor Suppressor ProteinsACTHAdrenal glandARMC5CortisolCushing’s syndromeGeneticsPrimary Bilateral Macronodular Adrenal Hyperplasia

Identifiers

PMID39910635
PMCPMC11796173

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.